Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26072921 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Bongkyun Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Natural Science, Kyungpook National University, Daegu 41944, Republic of Korea. Hauptthemen laut MEDLINE: Apoptosis, Tumor Suppressor Protein p53, Ovarian Neoplasms, Trabectedin. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daegu Catholic University, Daegu Catholic University Medical Center.
Abstract (Originalsprache)
This study investigated whether combining niraparib and trabectedin in BRCA-proficient epithelial ovarian cancer induces deficiencies in ssDNA break repair and dsDNA homologous recombination, leading to synthetic lethality. A2780 and SKOV3 ovarian cancer cell lines were treated with niraparib and trabectedin. Cell viability was assessed using CCK-8 assays, while RT-qPCR and Western blot analyzed the expression of DNA repair and apoptosis-related genes. Apoptosis was evaluated via Annexin V/PI assays. The combination therapy exhibited a synergistic effect on A2780 cells but not on SKOV3 cells. Treatment reduced BRCA1, BRCA2, RAD51, PARP1, and PARP2 expression, indicating impaired DNA repair. γ-H2AX levels increased, suggesting DNA damage. The therapy also upregulated p53, PUMA, NOXA, BAX, BAK, and p21, promoting p53-mediated apoptosis and cell cycle arrest. Apoptosis induction was confirmed via Annexin V/PI assays. Silencing p53 with siRNA abolished all synergistic effects in A2780 cells. Niraparib and trabectedin combination therapy impairs DNA repair in BRCA-proficient ovarian cancer, leading to synthetic lethality through p53-dependent apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, College of Natural Science, Kyungpook National University, Daegu 41944, Republic of Korea.
- Department of Pathology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
- Department of Radiation Oncology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
- Department of Obstetrics and Gynecology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
- Department of Biomedical and Pharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.
- Department of Pharmacology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
ORCID-Profile: Sun-Jae Lee, Ki Ho Seol, Jung-Hye Choi, Youn Seok Choi
Förderung
- Daegu Catholic University
- Daegu Catholic University Medical Center
Zitieren
APA
Kang, B., Lee, S. J., Seol, K. H., Jeong, Y. Y., Choi, J. H., Choi, B. H., Ryu, J. M., & Choi, Y. S. (2025). Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072921
Vancouver
Kang B, Lee SJ, Seol KH, Jeong YY, Choi JH, Choi BH, et al. Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072921
BibTeX
@article{Kang2025,
author = {Kang, Bongkyun and Lee, Sun-Jae and Seol, Ki Ho and Jeong, Yoon Young and Choi, Jung-Hye and Choi, Bo-Hyun and Ryu, Jung Min and Choi, Youn Seok},
title = {Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26072921}
}
EUVIMED